Liquidia Corporation — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; filed May 8, 2023. Unaudited consolidated results. Liquidia is a biopharmaceutical company focused on pulmonary hypertension. Current revenue is primarily its profit share from Sandoz’s generic treprostinil injection; its lead candidate, YUTREPIA, is an inhaled dry-powder treprostinil product that had FDA tentative approval but not final approval.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $4.5 million | $3.5 million |
| Cost of revenue | $0.7 million | $0.7 million |
| Gross profit and margin | $3.8 million; 85.4% | $2.8 million; 80.1% |
| Research and development | $5.3 million | $4.7 million |
| General and administrative | $7.8 million | $12.5 million |
| Operating loss | $(9.2) million | $(14.5) million |
| Net loss | $(11.7) million | $(15.9) million |
| Net loss per share, diluted | $(0.18) | $(0.30) |
| Operating cash flow | $(8.5) million | $(9.8) million |
Cash and cash equivalents were $94.4 million at March 31, 2023, compared with $93.3 million at year-end 2022. Cash increased $1.1 million in the quarter; investing activities used $0.4 million and financing activities provided $10.0 million. Total assets were $128.9 million, total liabilities $47.3 million, and stockholders’ equity $81.6 million. The accumulated deficit was $362.3 million.
Liquidia repaid its $20.0 million Silicon Valley Bank term loan in January using proceeds from its new HCR revenue-interest financing. At quarter-end, the HCR liability was $32.6 million, including $2.0 million classified as current; no SVB term debt remained. The facility provides for up to $100 million, but only $32.5 million had been funded by quarter-end. Additional funding is conditional and the arrangement includes royalty and fixed-payment obligations, covenants, and collateral provisions.
Changes versus the prior comparable period
- Revenue rose $1.0 million, or 29%, primarily from increased sales quantities and favorable gross-to-net rebate adjustments under the Sandoz Promotion Agreement.
- Operating loss narrowed by $5.2 million. G&A fell $4.7 million, mainly due to lower YUTREPIA litigation legal fees and lower stock-compensation expense, partly offset by increased commercialization preparation costs. R&D increased $0.6 million, primarily from consulting and personnel costs supporting potential commercialization.
- Net loss improved by $4.2 million despite higher net other expense. Q1 2023 included a $2.3 million loss on extinguishment of debt and higher interest expense; Q1 2022 included a $1.0 million extinguishment loss. Interest income increased substantially, to $0.9 million from less than $0.1 million.
- Operating cash use decreased by $1.3 million, although management attributed part of the year-over-year cash-flow movement to working-capital timing, including vendor payments.
Outlook, management commentary, risks, and unusual items
- Management expects significant expenses and operating losses to continue. It states that current cash, excluding future HCR tranches and YUTREPIA revenue, is expected to fund operations and capital needs for at least 12 months from issuance of the financial statements. If additional HCR amounts cannot be accessed, management warned that substantial doubt about going concern could arise by issuance of the Q2 2023 financial statements. Additional capital may be needed if contingent HCR funding is unavailable or meaningful YUTREPIA revenue is not generated.
- YUTREPIA commercialization timing is highly dependent on patent litigation. The Delaware court found the asserted ’793 patent valid and infringed and ordered that any final FDA approval not take effect before the patent’s 2027 expiration. Appeals by both parties were pending; oral argument occurred May 3, 2023. The PTAB had found the patent claims unpatentable, but that decision would not override the court order unless affirmed on appeal. A stay motion also remained pending.
- United Therapeutics’ separate trade-secret case remained in discovery. In the RareGen litigation, antitrust and unfair-competition claims were dismissed on summary judgment; a breach-of-contract damages trial was anticipated for summer 2023. Any Liquidia PAH proceeds would be subject to the litigation-financing arrangements.
- Treprostinil Injection sales face a device constraint: a shortage of a critical component has limited CADD-MS 3 pumps, and specialty pharmacies were not placing new patients on subcutaneous therapy to preserve pumps for existing patients. Smiths Medical’s support obligation ends January 1, 2025. Liquidia, Sandoz, and Mainbridge are developing a replacement pump; FDA clearance and timing are uncertain.
- Other material risks include YUTREPIA’s regulatory and commercial uncertainty, potential competing-product exclusivity, reliance on single-source suppliers for YUTREPIA inputs and devices, generic competition, and HCR facility draw conditions, covenants, and acceleration rights. The filing reports no known HCR covenant breach or default notice.
- On March 31, 2023, Liquidia entered a research license agreement with GSK for preclinical use of PRINT technology. GSK must obtain an expanded license for clinical or commercial use; Liquidia retains rights to apply PRINT to most inhaled formulations, subject to specified exclusions.
Important facts for investors to verify
- Developments and rulings in the Federal Circuit patent appeals, the stay motion, and the separate trade-secret litigation—and their effects on YUTREPIA’s potential approval and launch timing.
- Whether and when Liquidia can access the conditional HCR funding tranches, and the resulting cash runway, minimum-cash covenant compliance, and revenue-interest financing costs.
- Availability of CADD-MS 3 pumps and progress, FDA clearance, and commercial readiness of a replacement pump for Treprostinil Injection.
- Trends in Sandoz-related revenue, gross-to-net adjustments, customer concentration, and generic competition. The filing states one customer represented 99% of accounts receivable.
- YUTREPIA manufacturing readiness, supply continuity, potential exclusivity barriers, and commercialization spending relative to available cash.